TRADING UPDATES: Gfinity's Yentra partners with ESG Institute
17th Sep 2025 06:55
(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
| Price | 9.75p on 10-10-2025 at 08:48:18 |
|---|---|
| Change | 0.00p 0% |
| Buy | 10.00p |
| Sell | 9.50p |
| Last Trade: | Buy 11,320.00 at 9.90p |
| Day's Volume: | 32,585 |
| Last Close: | 9.75p |
| Open: | 9.75p |
| ISIN: | GB00B63D3314 |
| Day's Range | 9.75p - 10.00p |
| 52wk Range: | 7.25p - 17.50p |
| Market Capitalisation: | £101.18m |
| VWAP: | 9.850213p |
| Shares in Issue: | 1.04b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Scancell Holdings (SCLP) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 11,320 | 9.90p | Ordinary |
09:48:17 - 10-Oct-25 |
| Buy* | 11,244 | 9.80p | Ordinary |
09:18:50 - 10-Oct-25 |
| Buy* | 21 | 10.00p | Suspected BUY Trade |
09:00:09 - 10-Oct-25 |
| Buy* | 102,222 | 9.86p | Ordinary |
15:55:56 - 09-Oct-25 |
| Buy* | 101 | 9.84p | Ordinary |
15:55:12 - 09-Oct-25 |
| Buy* | 9,806 | 9.84p | Ordinary |
15:53:26 - 09-Oct-25 |
| Unknown* | 250,000 | 9.90p | Ordinary |
15:27:17 - 09-Oct-25 |
| Buy* | 749 | 9.86p | Ordinary |
15:12:26 - 09-Oct-25 |
| Unknown* | 250,000 | 10.00p | Negotiated Trade |
15:10:34 - 09-Oct-25 |
| Buy* | 25,000 | 9.86p | Ordinary |
14:54:17 - 09-Oct-25 |
Scancell Holdings (SCLP) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Oct 2025 7:00 am | RNS | Notice of AGM |
| 16th Sep 2025 7:00 am | RNS | Director Dealing |
| 11th Sep 2025 7:00 am | RNS | Final Results |
| 4th Sep 2025 7:00 am | RNS | Notice of Results |
| 8th Aug 2025 12:31 pm | RNS | Director Dealing |
| 4th Aug 2025 10:23 am | RNS | Director/PDMR Shareholding |
| 22nd Jul 2025 7:00 am | RNS | Strong Phase 2 data on iSCIB1+ in Melanoma |
| 16th Jul 2025 7:00 am | RNS | Share Option Exercise |
| 25th Jun 2025 7:00 am | RNS | Scancell initiates new arm in SCOPE Phase 2 study |
| 21st May 2025 7:00 am | RNS | Director Dealing |